Daewoong Pharmaceutical Co Ltd - Company Profile
Powered by 
All the data and insights you need on Daewoong Pharmaceutical Co Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date Daewoong Pharmaceutical Co Ltd Strategy Report
- Understand Daewoong Pharmaceutical Co Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Daewoong Pharmaceutical Co Ltd (Daewoong Pharmaceutical), a subsidiary of Daewoong Co Ltd, is a manufacturer and distributor of prescription drugs in South Korea. It offers prescription drugs, quasi drugs, healthcare products and APIs. The company produces products in the form of tablets, capsules, ointments, injections, liquids, and sprays. It offers products for conditions such as bone and joint diseases, cardiovascular diseases, central nervous system diseases, circulatory system, dermatological, gastrointestinal, and respiratory system remedies. It also carries out the development and commercialization of products through in-licensing, co-marketing and co-promotion. The company operates in Japan, the US, Canada, Switzerland, Germany, besides Indonesia, China, Vietnam, Israel, Thailand, and India in Asia. Daewoong Pharmaceutical is headquartered in Seoul, South Korea.
Headquarters
South Korea
Address
35-14, Jeyakgongdan 4-Gil, Hyangnam-Eup, Hwaseong, 18623
Website
www.daewoong.co.kr/kr/main/index
Telephone
82 25508800
No of Employees
1,256
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
069620 (KRX)
Revenue (2022)
$1.1B
7.4%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
188.2%
(2022 vs 2021)
Market Cap*
$917.1M
Net Profit Margin (2022)
XYZ
168.2%
(2022 vs 2021)
* As of and is in US$
Daewoong Pharmaceutical Co Ltd premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| - | - | - |
| Over the counter Drugs | CDMO service. | Nabota |
| Prescription Drugs | CareTropin | |
| XYZ | XYZ | |
| XYZ | XYZ | |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In November, the company entered into an agreement with Meheco to distribute the antacid Nulanta throughout China. |
| 2023 | Contracts/Agreements | In October, the company signed a memorandum of understanding with Merck Life Science to enhance AI-based new drug development. |
| 2023 | Others | In July, the company submitted a new drug application for Fexuprazan to Center for Drug Evaluation. |
Competitor Comparison
| Key Parameters | Daewoong Pharmaceutical Co Ltd | Yuhan Corp | GC Biopharma Corp | Dong-A Socio Holdings Co Ltd | Huons Global Co Ltd |
|---|---|---|---|---|---|
| Headquarters | South Korea | South Korea | South Korea | South Korea | South Korea |
| City | Hwaseong | Seoul | Yongin | Seoul | Seongnam |
| No. of Employees | 1,256 | 1,594 | 1,766 | 273 | 541 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Jeon Seungho | Co-Chief Executive Office | Senior Management | 2018 | 48 |
| Changjae Lee | Co-Chief Executive Officer | Senior Management | 2022 | 46 |
| Sungsoo Park | Director | Non Executive Board | 2023 | - |
| Hong-cheol Kim | Director | Non Executive Board | 2018 | 52 |
| Yong-jin Kim | Director | Non Executive Board | 2023 | 52 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward